Global GalNAc-Oligonucleotide Conjugates 麻豆原创 Research Report 2024

Publication ID:

PB511243215

Publication Date:

November 4, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

GalNAc-oligonucleotide conjugates refer to complexes formed by chemically linking N-acetylgalactosamine (GalNAc) molecules with oligonucleotides, such as small interfering RNA (siRNA). These conjugates leverage the properties of GalNAc to specifically target liver cells, thereby enhancing the delivery efficiency and therapeutic effect of the oligonucleotides. GalNAc-oligonucleotide conjugates demonstrate broad application potential in gene therapy, cancer treatment, and research and treatment of other related diseases, particularly in improving drug stability, enhancing cellular uptake, and reducing immunogenicity. This provides an innovative drug delivery strategy for modern medicine.
The global GalNAc-Oligonucleotide Conjugates market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for GalNAc-Oligonucleotide Conjugates is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for GalNAc-Oligonucleotide Conjugates is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of GalNAc-Oligonucleotide Conjugates include WuXi XDC, BOCSCI Inc., Creative Biogene, Creative Biolabs, Bachem, Biosynthesis, LGC Biosearch Technologies, Sinopep, Organix, CD Formulation, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for GalNAc-Oligonucleotide Conjugates, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GalNAc-Oligonucleotide Conjugates.
The GalNAc-Oligonucleotide Conjugates market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global GalNAc-Oligonucleotide Conjugates market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the GalNAc-Oligonucleotide Conjugates manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
WuXi XDC
BOCSCI Inc.
Creative Biogene
Creative Biolabs
Bachem
Biosynthesis
LGC Biosearch Technologies
Sinopep
Organix
CD Formulation
Maravai LifeSciences (Glen Research)
Hitgen
Alnylam Pharmaceuticals
by Type
GalNAc-siRNA Conjugates
GalNAc-ASO Conjugates
by Application
Liver Disorders
Cancer
Neurodegenerative Conditions
Other
Production by Region
North America
Europe
China
Japan
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of GalNAc-Oligonucleotide Conjugates manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of GalNAc-Oligonucleotide Conjugates in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 GalNAc-Oligonucleotide Conjugates 麻豆原创 Overview
1.1 Product Definition
1.2 GalNAc-Oligonucleotide Conjugates by Type
1.2.1 Global GalNAc-Oligonucleotide Conjugates 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 GalNAc-siRNA Conjugates
1.2.3 GalNAc-ASO Conjugates
1.3 GalNAc-Oligonucleotide Conjugates by Application
1.3.1 Global GalNAc-Oligonucleotide Conjugates 麻豆原创 Value by Application (2024-2030)
1.3.2 Liver Disorders
1.3.3 Cancer
1.3.4 Neurodegenerative Conditions
1.3.5 Other
1.4 Global GalNAc-Oligonucleotide Conjugates 麻豆原创 Size Estimates and Forecasts
1.4.1 Global GalNAc-Oligonucleotide Conjugates Revenue 2019-2030
1.4.2 Global GalNAc-Oligonucleotide Conjugates Sales 2019-2030
1.4.3 Global GalNAc-Oligonucleotide Conjugates 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 GalNAc-Oligonucleotide Conjugates 麻豆原创 Competition by Manufacturers
2.1 Global GalNAc-Oligonucleotide Conjugates Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global GalNAc-Oligonucleotide Conjugates Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global GalNAc-Oligonucleotide Conjugates Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of GalNAc-Oligonucleotide Conjugates, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of GalNAc-Oligonucleotide Conjugates, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of GalNAc-Oligonucleotide Conjugates, Product Type & Application
2.7 Global Key Manufacturers of GalNAc-Oligonucleotide Conjugates, Date of Enter into This Industry
2.8 Global GalNAc-Oligonucleotide Conjugates 麻豆原创 Competitive Situation and Trends
2.8.1 Global GalNAc-Oligonucleotide Conjugates 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest GalNAc-Oligonucleotide Conjugates Players 麻豆原创 Share by Revenue
2.8.3 Global GalNAc-Oligonucleotide Conjugates 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global GalNAc-Oligonucleotide Conjugates 麻豆原创 Scenario by Region
3.1 Global GalNAc-Oligonucleotide Conjugates 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global GalNAc-Oligonucleotide Conjugates Sales by Region: 2019-2030
3.2.1 Global GalNAc-Oligonucleotide Conjugates Sales by Region: 2019-2024
3.2.2 Global GalNAc-Oligonucleotide Conjugates Sales by Region: 2025-2030
3.3 Global GalNAc-Oligonucleotide Conjugates Revenue by Region: 2019-2030
3.3.1 Global GalNAc-Oligonucleotide Conjugates Revenue by Region: 2019-2024
3.3.2 Global GalNAc-Oligonucleotide Conjugates Revenue by Region: 2025-2030
3.4 North America GalNAc-Oligonucleotide Conjugates 麻豆原创 Facts & Figures by Country
3.4.1 North America GalNAc-Oligonucleotide Conjugates 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America GalNAc-Oligonucleotide Conjugates Sales by Country (2019-2030)
3.4.3 North America GalNAc-Oligonucleotide Conjugates Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe GalNAc-Oligonucleotide Conjugates 麻豆原创 Facts & Figures by Country
3.5.1 Europe GalNAc-Oligonucleotide Conjugates 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe GalNAc-Oligonucleotide Conjugates Sales by Country (2019-2030)
3.5.3 Europe GalNAc-Oligonucleotide Conjugates Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific GalNAc-Oligonucleotide Conjugates 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific GalNAc-Oligonucleotide Conjugates 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific GalNAc-Oligonucleotide Conjugates Sales by Region (2019-2030)
3.6.3 Asia Pacific GalNAc-Oligonucleotide Conjugates Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America GalNAc-Oligonucleotide Conjugates 麻豆原创 Facts & Figures by Country
3.7.1 Latin America GalNAc-Oligonucleotide Conjugates 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America GalNAc-Oligonucleotide Conjugates Sales by Country (2019-2030)
3.7.3 Latin America GalNAc-Oligonucleotide Conjugates Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa GalNAc-Oligonucleotide Conjugates 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa GalNAc-Oligonucleotide Conjugates 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa GalNAc-Oligonucleotide Conjugates Sales by Country (2019-2030)
3.8.3 Middle East and Africa GalNAc-Oligonucleotide Conjugates Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global GalNAc-Oligonucleotide Conjugates Sales by Type (2019-2030)
4.1.1 Global GalNAc-Oligonucleotide Conjugates Sales by Type (2019-2024)
4.1.2 Global GalNAc-Oligonucleotide Conjugates Sales by Type (2025-2030)
4.1.3 Global GalNAc-Oligonucleotide Conjugates Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global GalNAc-Oligonucleotide Conjugates Revenue by Type (2019-2030)
4.2.1 Global GalNAc-Oligonucleotide Conjugates Revenue by Type (2019-2024)
4.2.2 Global GalNAc-Oligonucleotide Conjugates Revenue by Type (2025-2030)
4.2.3 Global GalNAc-Oligonucleotide Conjugates Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global GalNAc-Oligonucleotide Conjugates Price by Type (2019-2030)
5 Segment by Application
5.1 Global GalNAc-Oligonucleotide Conjugates Sales by Application (2019-2030)
5.1.1 Global GalNAc-Oligonucleotide Conjugates Sales by Application (2019-2024)
5.1.2 Global GalNAc-Oligonucleotide Conjugates Sales by Application (2025-2030)
5.1.3 Global GalNAc-Oligonucleotide Conjugates Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global GalNAc-Oligonucleotide Conjugates Revenue by Application (2019-2030)
5.2.1 Global GalNAc-Oligonucleotide Conjugates Revenue by Application (2019-2024)
5.2.2 Global GalNAc-Oligonucleotide Conjugates Revenue by Application (2025-2030)
5.2.3 Global GalNAc-Oligonucleotide Conjugates Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global GalNAc-Oligonucleotide Conjugates Price by Application (2019-2030)
6 Key Companies Profiled
6.1 WuXi XDC
6.1.1 WuXi XDC Company Information
6.1.2 WuXi XDC Description and Business Overview
6.1.3 WuXi XDC GalNAc-Oligonucleotide Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.1.4 WuXi XDC GalNAc-Oligonucleotide Conjugates Product Portfolio
6.1.5 WuXi XDC Recent Developments/Updates
6.2 BOCSCI Inc.
6.2.1 BOCSCI Inc. Company Information
6.2.2 BOCSCI Inc. Description and Business Overview
6.2.3 BOCSCI Inc. GalNAc-Oligonucleotide Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.2.4 BOCSCI Inc. GalNAc-Oligonucleotide Conjugates Product Portfolio
6.2.5 BOCSCI Inc. Recent Developments/Updates
6.3 Creative Biogene
6.3.1 Creative Biogene Company Information
6.3.2 Creative Biogene Description and Business Overview
6.3.3 Creative Biogene GalNAc-Oligonucleotide Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Creative Biogene GalNAc-Oligonucleotide Conjugates Product Portfolio
6.3.5 Creative Biogene Recent Developments/Updates
6.4 Creative Biolabs
6.4.1 Creative Biolabs Company Information
6.4.2 Creative Biolabs Description and Business Overview
6.4.3 Creative Biolabs GalNAc-Oligonucleotide Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Creative Biolabs GalNAc-Oligonucleotide Conjugates Product Portfolio
6.4.5 Creative Biolabs Recent Developments/Updates
6.5 Bachem
6.5.1 Bachem Company Information
6.5.2 Bachem Description and Business Overview
6.5.3 Bachem GalNAc-Oligonucleotide Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Bachem GalNAc-Oligonucleotide Conjugates Product Portfolio
6.5.5 Bachem Recent Developments/Updates
6.6 Biosynthesis
6.6.1 Biosynthesis Company Information
6.6.2 Biosynthesis Description and Business Overview
6.6.3 Biosynthesis GalNAc-Oligonucleotide Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Biosynthesis GalNAc-Oligonucleotide Conjugates Product Portfolio
6.6.5 Biosynthesis Recent Developments/Updates
6.7 LGC Biosearch Technologies
6.7.1 LGC Biosearch Technologies Company Information
6.7.2 LGC Biosearch Technologies Description and Business Overview
6.7.3 LGC Biosearch Technologies GalNAc-Oligonucleotide Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.7.4 LGC Biosearch Technologies GalNAc-Oligonucleotide Conjugates Product Portfolio
6.7.5 LGC Biosearch Technologies Recent Developments/Updates
6.8 Sinopep
6.8.1 Sinopep Company Information
6.8.2 Sinopep Description and Business Overview
6.8.3 Sinopep GalNAc-Oligonucleotide Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Sinopep GalNAc-Oligonucleotide Conjugates Product Portfolio
6.8.5 Sinopep Recent Developments/Updates
6.9 Organix
6.9.1 Organix Company Information
6.9.2 Organix Description and Business Overview
6.9.3 Organix GalNAc-Oligonucleotide Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Organix GalNAc-Oligonucleotide Conjugates Product Portfolio
6.9.5 Organix Recent Developments/Updates
6.10 CD Formulation
6.10.1 CD Formulation Company Information
6.10.2 CD Formulation Description and Business Overview
6.10.3 CD Formulation GalNAc-Oligonucleotide Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.10.4 CD Formulation GalNAc-Oligonucleotide Conjugates Product Portfolio
6.10.5 CD Formulation Recent Developments/Updates
6.11 Maravai LifeSciences (Glen Research)
6.11.1 Maravai LifeSciences (Glen Research) Company Information
6.11.2 Maravai LifeSciences (Glen Research) Description and Business Overview
6.11.3 Maravai LifeSciences (Glen Research) GalNAc-Oligonucleotide Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Maravai LifeSciences (Glen Research) GalNAc-Oligonucleotide Conjugates Product Portfolio
6.11.5 Maravai LifeSciences (Glen Research) Recent Developments/Updates
6.12 Hitgen
6.12.1 Hitgen Company Information
6.12.2 Hitgen Description and Business Overview
6.12.3 Hitgen GalNAc-Oligonucleotide Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Hitgen GalNAc-Oligonucleotide Conjugates Product Portfolio
6.12.5 Hitgen Recent Developments/Updates
6.13 Alnylam Pharmaceuticals
6.13.1 Alnylam Pharmaceuticals Company Information
6.13.2 Alnylam Pharmaceuticals Description and Business Overview
6.13.3 Alnylam Pharmaceuticals GalNAc-Oligonucleotide Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Alnylam Pharmaceuticals GalNAc-Oligonucleotide Conjugates Product Portfolio
6.13.5 Alnylam Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 GalNAc-Oligonucleotide Conjugates Industry Chain Analysis
7.2 GalNAc-Oligonucleotide Conjugates Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 GalNAc-Oligonucleotide Conjugates Production Mode & Process
7.4 GalNAc-Oligonucleotide Conjugates Sales and 麻豆原创ing
7.4.1 GalNAc-Oligonucleotide Conjugates Sales Channels
7.4.2 GalNAc-Oligonucleotide Conjugates Distributors
7.5 GalNAc-Oligonucleotide Conjugates Customers
8 GalNAc-Oligonucleotide Conjugates 麻豆原创 Dynamics
8.1 GalNAc-Oligonucleotide Conjugates Industry Trends
8.2 GalNAc-Oligonucleotide Conjugates 麻豆原创 Drivers
8.3 GalNAc-Oligonucleotide Conjugates 麻豆原创 Challenges
8.4 GalNAc-Oligonucleotide Conjugates 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

WuXi XDC
BOCSCI Inc.
Creative Biogene
Creative Biolabs
Bachem
Biosynthesis
LGC Biosearch Technologies
Sinopep
Organix
CD Formulation
Maravai LifeSciences (Glen Research)
Hitgen
Alnylam Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.